The author argues that ERβ (especially ERβ1) exerts cancer-suppressive effects, such as oppressing the proliferative effects of ERα, inhibiting epidermal growth factor receptor (EGFR) and suppressing tumor bone metastasis (26–29). Here, ESR2 is linked to neoplasm.